The performance of remission criteria at baseline for the identification of patients without subsequent radiographic progression
| Baseline remission | Remission at baseline and no progression (%) | Not remission at baseline and no progression (%) | Sensitivity | Specificity | LR+ (95% CI) | Unadjusted OR (95% CI) |
|---|---|---|---|---|---|---|
| DAS28–CRP, n=106 | 70 | 58 | 0.24 | 0.84 | 1.5 (1.1 to 2.3) | 1.7 (1.1 to 2.7) p=0.02 |
| SDAI, n=37 | 76 | 59 | 0.09 | 0.96 | 2.1 (1.0 to 4.4) | 2.2 (1.0 to 4.8) p=0.04 |
| CDAI, n=26 | 81 | 59 | 0.07 | 0.98 | 2.8 (1.1 to 7.3) | 2.9 (1.1 to 7.9) p=0.03 |
| ACR/EULAR, n=30 | 80 | 60 | 0.07 | 0.97 | 2.7 (1.1 to 6.2) | 2.7 (1.1 to 6.7) p=0.03 |
| SJC 0, n=93 | 78 | 57 | 0.23 | 0.89 | 2.3 (1.4 to 3.6) | 2.6 (1.6 to 4.4) p<0.001 |
Sensitivity, specificity, positive likelihood ratios and logistic regression models, all with absence of progression as the outcome (good radiographic outcome, change in TSS <1 unit/year).
ACR, American College of Rheumatology; CDAI, clinical disease activity index; DAS28–CRP, disease activity score based on 28 joint count and C-reactive protein; EULAR, European League Against Rheumatism; LR+, positive likelihood ratio; SDAI, simplified disease activity index; SJC, swollen joint count; TSS, van der Heijde modified Sharp score.